PT-141 (Bremelanotide)

PT-141 is a synthetic melanocortin receptor agonist derived from the α-melanocyte-stimulating hormone (α-MSH) peptide family. It primarily acts on central melanocortin receptors (notably MC3R and MC4R) within the hypothalamus, influencing sexual arousal pathways independent of vascular mechanisms. Unlike phosphodiesterase inhibitors, PT-141 exerts its effects through modulation of neural signaling, increasing dopamine activity and enhancing libido at the central nervous system level. This distinct mechanism has led to its investigation and eventual FDA approval (as bremelanotide) for hypoactive sexual desire disorder (HSDD) in premenopausal women.

In clinical and preclinical studies, PT-141 has demonstrated the ability to improve sexual desire, arousal, and satisfaction in both men and women, with effects linked to its action on neuroendocrine pathways. Additional research suggests potential influences on mood and reward circuits due to melanocortin system involvement. While generally well tolerated in controlled settings, reported side effects include transient nausea, flushing, and increases in blood pressure. Ongoing research continues to explore its broader neurobehavioral effects and therapeutic applications beyond sexual dysfunction.